Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebif vs Avonex in Relapsing-Remitting Multiple Sclerosis
NCT00292266Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Nov 1999
- Primary completion
- Jun 2002
- Modality
- Cytokines & Interferons
01
Overview
Phase 3, randomised, open-label trial of interferon beta in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by EMD Serono. Primary endpoint: Percentage of exacerbation-free subjects at 72 weeks. Started Nov 1999; status: completed.
02
Drugs
interferon beta
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00292266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00292266.